Ultimovacs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Ultimovacs şirketinin toplam hissedar öz sermayesi NOK191.0M ve toplam borcu NOK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NOK215.8M ve NOK24.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

NOK 0

Borç

Faiz karşılama oranı	n/a
Nakit	NOK 131.00m
Eşitlik	NOK 191.01m
Toplam yükümlülükler	NOK 24.78m
Toplam varlıklar	NOK 215.79m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 7UM 'nin kısa vadeli varlıkları ( NOK140.1M ) kısa vadeli yükümlülüklerini ( NOK12.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: 7UM şirketinin kısa vadeli varlıkları ( NOK140.1M ) uzun vadeli yükümlülüklerini ( NOK12.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 7UM borçsuzdur.

Borcun Azaltılması: 7UM un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 7UM şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 7UM serbest nakit akışı her yıl % 22 1.5 yıl yetecek nakit akışına sahip olacaktır.

Ultimovacs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Ultimovacs ASA Announces Publication of Phase II FOCUS Trial Results on MedRxiv

New minor risk - Financial position

Ultimovacs ASA Announces Resignation of Ketil Fjerdingen as Deputy Board Member

Ultimovacs ASA Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer

Ultimovacs Asa Announces Poster Presentation of Nipu Phase II Trial Update At Upcoming ESMO Congress 2024

Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma

No longer forecast to breakeven

Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program

Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma

Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma

Ultimovacs ASA to Report Q4, 2024 Results on Feb 13, 2025

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

New minor risk - Profitability

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma

Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024

Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid

Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)

Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine

Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma

Ultimovacs ASA Announces the Results from Uv1 Phase Ii Clinical Trial Nipu in Malignant Mesothelioma Will Be Presented At the Esmo Congress 2023

Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients

Ultimovacs ASA Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results

Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine

New major risk - Share price stability

Ultimovacs ASA Provides Update on Phase II NIPU Trial Evaluating UV1 in Second-Line Patients with Malignant Leural Mesothelioma

Forecast breakeven date pushed back to 2024

No independent directors

Ultimovacs ASA Announces Completion of Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Ultimovacs ASA Announces Cemiplimab to Replace Pembrolizumab in V1 Phase II LUNGVAC Trial

Ultimovacs ASA Completes Last Patient Enrollment in Phase I TENDU Trial in Prostate Cancer

Forecast to breakeven in 2023

No independent directors

No longer forecast to breakeven

Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs ASA Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma

Ultimovacs ASA Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

Ultimovacs ASA Expands High Dose Cohort Size in Tendu Phase I Prostate Cancer Trial After Safety Review

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

Ultimovacs ASA Announces UV1 Cancer Vaccine Shows Strong Overall Survival in Malignant Melanoma Phase I Trial

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data At Cancer Immunotherapy Annual Meeting

No independent directors

Ultimovacs ASA Approves Board and Committee Changes

Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

Ultimovacs ASA Completes Treatment of the Second Dose Cohort in the Phase I TENDU Trial

Ultimovacs ASA Announces First Patient Enrolled in Phase II DOVACC Trial of UV1 in Advanced Ovarian Cancer

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Ultimovacs Asa Announces Further Positive Topline Results from Phase I Uv1 Cancer Vaccine Combination Study in Metastatic Melanoma

Ultimovacs Announces First Patient Enrolled in Phase II Focus Trial of UV1 in Head-And-Neck Cancer

Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines

Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

Ultimovacs ASA Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

Deputy Board Member recently bought €38k worth of stock

Forecast to breakeven in 2023

Ultimovacs ASA’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data

Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology

Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Insider recently sold €406k worth of stock

Ultimovacs ASA to Report Q1, 2021 Results on May 11, 2021

Ultimovacs Announces to Participate in a Phase II Study in Collaboration with Astrazeneca

Ultimovacs ASA Announces Phase II DOVACC Collaboration Study in Ovarian Cancer With the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca

Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab

New 90-day high: €7.48

Ultimovacs ASA Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma

New 90-day high: €5.62

Ultimovacs Announces the Appointment of Ton Berkien as Chief Business Officer, Effective December 1, 2020